Leerink Partnrs Has Bearish Forecast for Danaher Q1 Earnings

Danaher Co. (NYSE:DHR) – Investment analysts at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Danaher in a research note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings of $2.02 per share for the quarter, down from their previous estimate of $2.06. The consensus estimate for Danaher’s current full-year earnings is $7.50 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2025 earnings at $1.88 EPS, Q3 2025 earnings at $1.86 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $8.22 EPS and FY2026 earnings at $9.22 EPS.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company earned $2.02 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year.

A number of other research analysts have also weighed in on DHR. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday. Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $287.95.

Danaher Price Performance

Shares of NYSE DHR opened at $234.36 on Monday. The stock has a market capitalization of $169.27 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher has a 52 week low of $222.53 and a 52 week high of $281.70. The firm has a 50-day simple moving average of $246.23 and a 200-day simple moving average of $257.30. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in Danaher in the second quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth approximately $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at approximately $40,000. Finally, FSA Wealth Management LLC purchased a new position in shares of Danaher during the third quarter worth approximately $50,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.